Ozempic and Heart Disease: What the SELECT Trial Means for You

In August 2023, the New England Journal of Medicine published results from the SELECT trial — one of the most important cardiovascular studies in recent memory. Semaglutide didn’t just help people lose weight. It significantly reduced the risk of heart attacks, strokes, and cardiovascular death in people who’d already had a heart attack or stroke. Here’s what the data means and why it matters.

What the SELECT Trial Found

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 adults who:

• Had established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease)
• Had BMI ≥27
• Did NOT have type 2 diabetes

After an average follow-up of 40 months, patients on semaglutide 2.4 mg had:

• 20% reduction in major adverse cardiovascular events (MACE) — the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke
• Significant reductions in each individual component of MACE
• Average weight loss of ~9.4% of body weight
• Improvements in blood pressure, CRP (inflammation marker), and waist circumference

This was landmark for two reasons: it was the first large trial to show cardiovascular benefit from a GLP-1 medication specifically in non-diabetic patients with obesity, and the 20% risk reduction is clinically substantial — comparable to adding a statin in high-risk patients.

Why This Changes Who Should Take Semaglutide

Before SELECT, GLP-1 cardiovascular benefit data (LEADER with liraglutide, SUSTAIN-6 with semaglutide) was limited to patients with type 2 diabetes. The general assumption was that cardiovascular benefits were partly mediated through blood sugar improvement.

SELECT showed the benefit occurs even without diabetes — meaning the cardiovascular protection is at least partly independent of glycemic effects. This shifts GLP-1 medications from “weight loss drugs with some CV benefit in diabetics” to “medications with proven cardiovascular benefit in a broader high-risk population.”

The FDA updated Wegovy’s label in March 2024 to include a cardiovascular risk reduction indication — the first weight loss drug to receive this designation. This also opened the door for Medicare to cover Wegovy for cardiovascular risk reduction, not just weight loss.

How Does Semaglutide Protect the Heart?

Researchers are still working out the exact mechanisms. Multiple pathways appear to contribute:

Mechanism	What It Does
Weight loss	Reduces cardiac workload, blood pressure, inflammation
Blood pressure reduction	Lower BP directly reduces stroke and MI risk
Anti-inflammatory effects	Reduces CRP and systemic inflammation linked to atherosclerosis
Direct cardiac GLP-1 receptor effects	GLP-1 receptors on heart cells may have direct cardioprotective effects
Improved lipid profile	Modest reductions in triglycerides and LDL
Reduced platelet aggregation	May reduce blood clot formation

The fact that cardiovascular benefit appeared relatively early (within 6 months) in SELECT — before significant weight loss could account for it — suggests direct drug effects on the cardiovascular system beyond just weight reduction.

Does Ozempic Also Protect the Heart?

Yes — earlier data from the SUSTAIN-6 trial showed semaglutide (at Ozempic doses) reduced major cardiovascular events by 26% in patients with type 2 diabetes and high CV risk. SELECT expanded this to non-diabetic patients at higher doses (2.4 mg/Wegovy).

Cardiologists are increasingly factoring GLP-1 medications into treatment plans for high-risk cardiac patients — particularly those with obesity, heart failure with preserved ejection fraction (HFpEF), or recent ACS events.

What About Tirzepatide?

Tirzepatide (Zepbound/Mounjaro) is being studied in the SURPASS-CVOT trial for cardiovascular outcomes in T2D, and the SURMOUNT-MMO trial for CV outcomes in obesity without T2D. Results from these trials will help clarify whether tirzepatide matches or exceeds semaglutide’s cardiovascular benefits.

Frequently Asked Questions

Does Ozempic reduce heart attack risk?

Yes. The SUSTAIN-6 trial showed a 26% reduction in MACE with semaglutide in high-risk T2D patients. The SELECT trial showed a 20% reduction in MACE with Wegovy (semaglutide 2.4 mg) in non-diabetic patients with established cardiovascular disease and obesity.

Can Wegovy be used for heart disease?

Yes — in March 2024, the FDA approved an additional indication for Wegovy: reduction of cardiovascular risk (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and BMI ≥27. This is the first weight loss medication to receive a CV risk reduction label.

Does Medicare cover Wegovy for heart disease?

Medicare Part D can now cover Wegovy for patients with established cardiovascular disease (qualifying as the SELECT trial population), as the Inflation Reduction Act and subsequent CMS guidance opened coverage for medications with proven cardiovascular benefit. Check with your specific Part D plan for formulary details, as coverage implementation varies.